Published on 8 May 2024 on Zacks via Yahoo Finance
Apellis Pharmaceuticals (APLS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended March 2024, Apellis Pharmaceuticals, Inc. (APLS) reported revenue of $172.33 million, up 284.2% over the same period last year. EPS came in at -$0.54, compared to -$1.56 in the year-ago quarter.
The reported revenue compares to the Zacks Consensus Estimate of $160.51 million, representing a surprise of +7.36%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.54.